These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 12557698)

  • 1. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
    Kuruma H; Egawa S
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer.
    Kamoi K; Babaian RJ
    Semin Oncol; 1999 Apr; 26(2):140-9. PubMed ID: 10597725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prostate-specific antigen].
    Eide IA; Angelsen A
    Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2528-31. PubMed ID: 11070990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
    Egawa S; Suyama K; Matsumoto K; Kuwao S; Baba S
    J Urol; 2002 Jan; 167(1):97-102. PubMed ID: 11743284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Free/total ratio of prostate-specific antigen (PSA) for prostate cancer detection in patients with gray zone PSA level].
    Tanaka M; Murakami S; Igarashi T; Abe T; Suzuki K; Sekita N; Shimazaki J
    Hinyokika Kiyo; 1997 Dec; 43(12):855-60. PubMed ID: 9488932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer].
    Nutahara K; Higashihara E
    Rinsho Byori; 2001 Oct; 49(10):963-6. PubMed ID: 11769472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF; Mensink HJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
    Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
    Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N; Ohyama C; Habuchi T
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
    Yamanaka K; Yamada Y; Kobayashi Y; Ueno K; Takechi Y; Hasegawa E; Chikahira Y
    Hinyokika Kiyo; 2003 Jan; 49(1):5-10. PubMed ID: 12629773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
    Stephan C; Jung K; Lein M; Sinha P; Schnorr D; Loening SA
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1133-47. PubMed ID: 11097220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined use of PSA density and free to total PSA ratio for cancer detection from patients with PSA elevations].
    Kawai M; Okajima K; Kobayashi K; Moriyama M
    Hinyokika Kiyo; 2006 Feb; 52(2):113-7. PubMed ID: 16541764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of PSA-density: analysis in PSA gray zone cases].
    Ishizuka O; Iwata K; Igawa Y; Nishizawa O
    Hinyokika Kiyo; 2001 Sep; 47(9):611-3. PubMed ID: 11692595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical evaluation of tandem PSA for the diagnosis and follow-up of prostate cancer].
    Okaneya T; Mizusawa H; Taguchi I; Yoneyama T
    Hinyokika Kiyo; 1996 Nov; 42(11):861-7. PubMed ID: 8973936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prostate cancer].
    Uchida K; Akaza H
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1469-74. PubMed ID: 11681260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
    Aksoy Y; Oral A; Aksoy H; Demirel A; Akcay F
    Ann Clin Lab Sci; 2003; 33(3):320-3. PubMed ID: 12956448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.